Lydia Tabernero

Founder at TaBriX ltd.

Presenter

Prof. of Structural Biology and Drug Discovery, Univ. of Manchester. Founder of TaBriX Ltd. Lydia Tabernero (LT), TaBriX, Manchester, UK, has >25 years of experience managing national/international collaborative research projects. She is world-leader in phosphatase functional/structural characterisation, and responsible for drug development programmes targeting M.tuberculosis (Mtb) phosphatases. She pioneered the characterisation of the MptpB and SapM phosphatases critical for Mtb pathogenesis and intracellular survival in the host. She developed novel inhibitors that reduce Mtb and M.avium infection in vivo and unveiled a new family of orthologues of MptpB in >300 human pathogens as potential pharmaceutical targets. This work, resulted in significant impact publications and led to important collaborations with pharmaceutical companies (Abbott Laboratories, GSK, RedX, Evotec, F2G, LifeArc). The assets generated from this work and collaborations formed the basis of a new spin-out company, TaBrix Ltd. founded in 2021 (https://tabrix.co.uk). TaBriX developed small-molecule drugs that restore immune clearance of mycobacteria to reduce treatment duration and improve quality of life for patients. This pioneer approach is applicable to drug resistant and chronic infections and increases efficacy on standard-of-care antibiotics. (https://orcid.org/0000-0001-8867-455X). Her H-index is 33 and I10-index 52 with 3389 citations.